TenQ · fact sheet · filings current to · price as of
Regeneron Pharmaceuticals (REGN)
Strong business, priced for a lot of it - 26 of 36 checks passed.
Latest close : $827.72, -1.9% on the day; -2.9% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $827.72 |
| Market cap | $78.1B |
| 52-week range | $552.68 - $852.03 |
| P/E | 20.8x |
| P/E, own 11-year median | 18.4x |
| P/S | 5.0x |
| Free cash flow yield | 4.8% |
| Dividend yield | 0.5% |
| Revenue (TTM) | $15.5B |
| Net income (TTM) | $4.3B |
| Free cash flow (TTM) | $3.8B |
| Gross margin | 98.6% |
| Operating margin | 24.7% |
| Return on equity | 13.7% |
| Revenue growth (1y) | +9.3% |
| Revenue CAGR (3y) | +5.6% |
| Debt / equity | 0.06x |
| Cash & short-term investments | $8.0B |
| Shares outstanding | 94.4m (reported shares outstanding, 2012-09-30) |
The score: 26 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is REGN stock cheap or expensive right now?
Value · 2 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Regeneron Pharmaceuticals still growing?
Growth · 2 of 6 checks passed. Growth is weak or inconsistent - the trend, not the story, is the problem. chapter →
Does Regeneron Pharmaceuticals make real money?
Quality · 6 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Regeneron Pharmaceuticals survive a bad year?
Health · 6 of 6 checks passed. A fortress balance sheet - REGN can survive a very bad year. chapter →
What does Regeneron Pharmaceuticals hand back to shareholders?
Shareholder returns · 4 of 6 checks passed. Cash comes back to owners, with a caveat or two in the checks below. chapter →
Which way is REGN trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling REGN?
Open-market buys: $0.00 · sells: $5M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.